Praxis Precision Medicines, Inc. (PRAX) Research

Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.

Market snapshot

Symbol
PRAX
Price
$282.31
Day change
+4.56%
Market cap
$6.0B
P/E ratio
-24.97x
52-week range
37.19-366.52
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 1 month
Analyst price target
$584

Recent news

  • Praxis Reassesses Vormatrigine Program After Pivotal Epilepsy Study Misses Primary Endpoint

    Praxis Precision Medicines Inc. (NASDAQ:PRAX) on Monday reported results from its Phase 2/3 POWER1 study of vormatrigine for focal onset seizures.

  • Praxis Precision's epilepsy drug misses main goal of mid-to-late stage study

    Praxis Precision Medicines said on Monday its experimental epilepsy drug failed to meet the ​main goal of a mid- to late-stage ‌study, prompting it to pause enrollment in another ongoing study while it reassesses the program.

  • Praxis Stock Rises After Elsunersen Shows 77% Seizure Reduction In Trial

    Praxis said elsunersen demonstrated a placebo-adjusted seizure reduction from baseline of 77% (p=0.015) in pediatric patients with SCN2A developmental and epileptic encephalopathy.

Peer companies

  • ACADIA Pharmaceuticals Inc. (ACAD)
  • Akero Therapeutics, Inc. (AKRO)
  • Centessa Pharmaceuticals plc (CNTA)
  • Crinetics Pharmaceuticals, Inc. (CRNX)
  • Immunovant, Inc. (IMVT)
  • Kymera Therapeutics, Inc. (KYMR)
  • Ligand Pharmaceuticals Incorporated (LGND)
  • Soleno Therapeutics, Inc. (SLNO)

Recent insider activity

  • Arbuckle Stuart A — A-Award (1371 shares) on 2026-06-10
  • Arbuckle Stuart A — A-Award (648 shares) on 2026-06-10
  • Chodakewitz Jeffrey — A-Award (1371 shares) on 2026-06-10
  • Chodakewitz Jeffrey — A-Award (648 shares) on 2026-06-10
  • YOUNG WILLIAM D — A-Award (1371 shares) on 2026-06-10

Open Praxis Precision Medicines, Inc. (PRAX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.